GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Cyclically Adjusted PB Ratio

Atossa Therapeutics (FRA:YAG2) Cyclically Adjusted PB Ratio : 0.09 (As of Jul. 01, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-07-01), Atossa Therapeutics's current share price is €0.752. Atossa Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €8.01. Atossa Therapeutics's Cyclically Adjusted PB Ratio for today is 0.09.

The historical rank and industry rank for Atossa Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:YAG2' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.11
Current: 0.11

During the past years, Atossa Therapeutics's highest Cyclically Adjusted PB Ratio was 0.11. The lowest was 0.00. And the median was 0.00.

FRA:YAG2's Cyclically Adjusted PB Ratio is ranked better than
88.69% of 681 companies
in the Biotechnology industry
Industry Median: 1.5 vs FRA:YAG2: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Atossa Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was €0.468. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.01 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Atossa Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Atossa Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Cyclically Adjusted PB Ratio Chart

Atossa Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.04 0.01 0.03 0.09

Atossa Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.07 0.12 0.09 0.08

Competitive Comparison of Atossa Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Atossa Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Atossa Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Atossa Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.752/8.01
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Atossa Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.468/134.9266*134.9266
=0.468

Current CPI (Mar. 2025) = 134.9266.

Atossa Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 72.634 100.684 97.337
201509 47.763 100.392 64.194
201512 18.978 99.792 25.660
201603 15.685 100.470 21.064
201606 9.750 101.688 12.937
201609 15.266 101.861 20.222
201612 9.291 101.863 12.307
201703 4.522 102.862 5.932
201706 2.986 103.349 3.898
201709 1.839 104.136 2.383
201712 2.211 104.011 2.868
201803 1.609 105.290 2.062
201806 2.383 106.317 3.024
201809 1.640 106.507 2.078
201812 1.324 105.998 1.685
201903 1.891 107.251 2.379
201906 1.701 108.070 2.124
201909 1.493 108.329 1.860
201912 1.297 108.420 1.614
202003 1.080 108.902 1.338
202006 0.799 108.767 0.991
202009 0.801 109.815 0.984
202012 0.470 109.897 0.577
202103 0.971 111.754 1.172
202106 0.950 114.631 1.118
202109 0.949 115.734 1.106
202112 0.965 117.630 1.107
202203 0.969 121.301 1.078
202206 0.973 125.017 1.050
202209 0.988 125.227 1.065
202212 0.879 125.222 0.947
202303 0.835 127.348 0.885
202306 0.765 128.729 0.802
202309 0.735 129.860 0.764
202312 0.666 129.419 0.694
202403 0.629 131.776 0.644
202406 0.592 132.554 0.603
202409 0.528 133.029 0.536
202412 0.528 133.157 0.535
202503 0.468 134.927 0.468

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atossa Therapeutics  (FRA:YAG2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Atossa Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atossa Therapeutics Business Description

Traded in Other Exchanges
Address
10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Headlines

No Headlines